For the Inventor, By the Inventor

Enter assignee name

Mississauga, Canada

Hyal Pharmaceutical Corporation

USPTO Granted Patents = 41

Forward Citations = 699

Loading Chart...

Loading Chart...

16 inventors (with patents filed for the assignee):

Samuel Simon Asculai (36 out of 38 patents)

Rudolf Edgar Falk (30 out of 33 patents)

Ehud Shmuel Klein (11 out of 11 patents)

4. David William Harper (11 out of 11 patents)

5. David Hochman (10 out of 10 patents)

6. Don Purschke (10 out of 10 patents)

7. Rudolf Edger Falk (6 out of 6 patents)

8. Eva Anne Turley (5 out of 11 patents)

9. Alan Drizen (3 out of 4 patents)

10. Anthony E Bolton (1 out of 17 patents)

11. Samuel Simon Ascuali (1 out of 2 patents)

12. Chandan Alam (1 out of 2 patents)

13. Derek A Willoughby (1 out of 3 patents)

14. Anita Aviad (1 out of 1 patent)

15. Stefan Gustafson (1 out of 1 patent)

Core Competencies:

Hyaluronic Acid

Topical Composition

Therapeutic Methods

Arterial Restenosis

NSAIDs

Angiogenesis Inhibition

Ischemia Reperfusion Repair

Macrophage Treatment

Formulations Development

Peritoneal Dialysis Applications

Basal Cell Carcinoma

Equine Navicular Disease

41 patents: Sort by Forward Citations

1. 6218373 - Formulations containing hyaluronic acid (2001-04-17),

2. 6194392 - Treatment of conditions and disease (2001-02-27),

3. 6147059 - Formulations containing hyaluronic acid (2000-11-14),

4. 6140312 - Formulations containing hyaluronic acid (2000-10-31),

5. 6136793 - Formulations containing hyaluronic acid (2000-10-24),

6. 6114314 - Formulations containing hyaluronic acid (2000-09-05),

7. 6103704 - Therapeutic methods using hyaluronic acid (2000-08-15),

8. 6087344 - Formulations containing hyaluronic acid (2000-07-11),

9. 6069135 - Use of hyaluronic acid or its derivatives to enhance delivery of (2000-05-30),

10. 6048844 - Treatment of conditions and disease (2000-04-11),

11. 6022866 - Use of hyaluronic acid and forms to prevent arterial restenosis (2000-02-08),

12. 6017900 - Topical composition containing hyaluronic acid and nsaids (2000-01-25),

13. 5990096 - Formulations containing hyaluronic acid (1999-11-23),

14. 5990095 - Use of hyaluronic acid and forms to prevent arterial restenosis (1999-11-23),

15. 5985851 - Use of hyaluronic acid or its derivatives in peritoneal dialysis and (1999-11-16),

Hyal Pharmaceutical Corporation is a leading global pharmaceutical company specializing in the development and production of innovative healthcare solutions. With a strong emphasis on research and development, Hyal Pharma is dedicated to addressing unmet medical needs and improving the lives of patients worldwide. Our wide range of therapeutic products spans various medical fields, including cardiovascular, oncology, neuroscience, and rare diseases. Hyal Pharma’s commitment to quality, safety, and effectiveness ensures the highest standards in our products, while our dedicated team of professionals strive to deliver innovative treatments that make a significant impact on patient care.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 20 2026

41 Patents

#21 in Mississauga

#323 in Canada

#16,241 in the World

Mississauga, Canada

Hyal Pharmaceutical Corporation

Forward Citations = 699

16 inventors:

Samuel Simon Asculai (36 out of 38 patents)

Rudolf Edgar Falk (30 out of 33 patents)

Ehud Shmuel Klein (11 out of 11 patents)

4. David William Harper (11 out of 11 patents)

5. David Hochman (10 out of 10 patents)

Please report any incorrect information to support@idiyas.com

Loading…